Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Beta-Hydroxy-Beta-Methylbutyrate in Amyotrophic Lateral Sclerosis: NCT07589764 Clinical Landscape Report 2026
9 min read
Beta-Hydroxy-Beta-Methylbutyrate in Amyotrophic Lateral Sclerosis: NCT07589764 Clinical Landscape Report 2026
16 September 2026
NCT07589764 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
p95HER2.CAR-TECH2Me T cells (Vall d'Hebron Institut d'Oncologia) in Metastatic endometrial cancer: NCT07593820 Clinical Landscape Report 2026
9 min read
p95HER2.CAR-TECH2Me T cells (Vall d'Hebron Institut d'Oncologia) in Metastatic endometrial cancer: NCT07593820 Clinical Landscape Report 2026
16 September 2026
NCT07593820 clinical landscape for Metastatic endometrial cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
HW241045 in Idiopathic Pulmonary Fibrosis: NCT07593690 Clinical Landscape Report 2026
9 min read
HW241045 in Idiopathic Pulmonary Fibrosis: NCT07593690 Clinical Landscape Report 2026
16 September 2026
NCT07593690 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Bendamustine Hydrochloride in High grade B-cell lymphoma: NCT07593482 Clinical Landscape Report 2026
9 min read
Bendamustine Hydrochloride in High grade B-cell lymphoma: NCT07593482 Clinical Landscape Report 2026
16 September 2026
NCT07593482 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
RD-0605 in Idiopathic Inflammatory Myopathies: NCT07596680 Clinical Landscape Report 2026
9 min read
RD-0605 in Idiopathic Inflammatory Myopathies: NCT07596680 Clinical Landscape Report 2026
16 September 2026
NCT07596680 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
Read →
RPH-035 in Multiple Sclerosis, Secondary Progressive: NCT07597668 Clinical Landscape Report 2026
9 min read
RPH-035 in Multiple Sclerosis, Secondary Progressive: NCT07597668 Clinical Landscape Report 2026
16 September 2026
NCT07597668 clinical landscape for Multiple Sclerosis, Secondary Progressive: endpoints, sponsor, phase, geography, readouts, asset context and development w…
Read →
KUP-101 in Mucosal Melanoma: NCT07600476 Clinical Landscape Report 2026
9 min read
KUP-101 in Mucosal Melanoma: NCT07600476 Clinical Landscape Report 2026
16 September 2026
NCT07600476 clinical landscape for Mucosal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Mosunetuzumab in Lupus Nephritis: NCT07598396 Clinical Landscape Report 2026
9 min read
Mosunetuzumab in Lupus Nephritis: NCT07598396 Clinical Landscape Report 2026
16 September 2026
NCT07598396 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Lenalidomide in Multiple Myeloma: NCT07600151 Clinical Landscape Report 2026
9 min read
Lenalidomide in Multiple Myeloma: NCT07600151 Clinical Landscape Report 2026
16 September 2026
NCT07600151 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
SYH2059 in Idiopathic Pulmonary Fibrosis: NCT07600021 Clinical Landscape Report 2026
9 min read
SYH2059 in Idiopathic Pulmonary Fibrosis: NCT07600021 Clinical Landscape Report 2026
16 September 2026
NCT07600021 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
DCY636 in Dermatitis, Atopic: NCT07604324 Clinical Landscape Report 2026
9 min read
DCY636 in Dermatitis, Atopic: NCT07604324 Clinical Landscape Report 2026
16 September 2026
NCT07604324 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
MT-125 in Glioblastoma, IDH-Wildtype: NCT07604285 Clinical Landscape Report 2026
9 min read
MT-125 in Glioblastoma, IDH-Wildtype: NCT07604285 Clinical Landscape Report 2026
16 September 2026
NCT07604285 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →